Jim Cramer on Amgen: “The Biotech Really Impressed Me With a Very Strong Pipeline”

Group 1 - Amgen Inc. is highlighted as a stock with strong potential due to positive feedback received at the JPMorgan Healthcare Conference, emphasizing its robust pipeline and good earnings [1] - The company is recognized for delivering human therapeutics for various conditions, including cancer and cardiovascular diseases, with a notable mention of its cholesterol drug, Repatha, which helps prevent heart attacks [2] - The investment community acknowledges Amgen's potential but suggests that certain AI stocks may offer greater upside potential and lower downside risk [2]